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Neuromuscular magnetic 
stimulation counteracts muscle 
decline in ALs patients: results 
of a randomized, double-blind, 
controlled study
Antonio Musarò  1,2, Gabriella Dobrowolny1,2, Chiara Cambieri3, emanuela onesti3, 
Marco Ceccanti3, Vittorio Frasca3, Annalinda pisano4, Bruna Cerbelli4,5, elisa Lepore1, 
Gabriele Ruffolo6,8, pierangelo Cifelli7, Cristina Roseti8, Carla Giordano  4, 
Maria Cristina Gori3, eleonora palma6 & Maurizio Inghilleri3
the aim of the study was to verify whether neuromuscular magnetic stimulation (NMMs) improves 
muscle function in spinal-onset amyotrophic lateral sclerosis (ALs) patients. twenty-two ALs patients 
were randomized in two groups to receive, daily for two weeks, NMMs in right or left arm (referred to 
as real-NMMs, rNMMs), and sham NMMs (sNMMs) in the opposite arm. All the patients underwent a 
median nerve conduction (compound muscle action potential, CMAp) study and a clinical examination 
that included a handgrip strength test and an evaluation of upper limb muscle strength by means of 
the Medical Research Council Muscle scale (MRC). Muscle biopsy was then performed bilaterally on 
the flexor carpi radialis muscle to monitor morpho-functional parameters and molecular changes. 
patients and physicians who performed examinations were blinded to the side of real intervention. 
the primary outcome was the change in the muscle strength in upper arms. the secondary outcomes 
were the change from baseline in the CMAp amplitudes, in the nicotinic ACh currents, in the expression 
levels of a selected panel of genes involved in muscle growth and atrophy, and in histomorphometric 
parameters of ALS muscle fibers. The Repeated Measures (RM) ANOVA with a Greenhouse-Geisser 
correction (sphericity not assumed) showed a significant effect [F(3, 63) = 5.907, p < 0.01] of rNMMS 
on MRC scale at the flexor carpi radialis muscle, thus demonstrating that the rNMMS significantly 
improves muscle strength in flexor muscles in the forearm. Secondary outcomes showed that the 
improvement observed in rNMMs-treated muscles was associated to counteracting muscle atrophy, 
down-modulating the proteolysis, and increasing the efficacy of nicotinic ACh receptors (AChRs). We did 
not observe any significant difference in pre- and post-stimulation CMAP amplitudes, evoked by median 
nerve stimulation. this suggests that the improvement in muscle strength observed in the stimulated 
arm is unlikely related to reinnervation. the real and sham treatments were well tolerated without 
evident side effects. Although promising, this is a proof of concept study, without an immediate clinical 
translation, that requires further clinical validation.
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Amyotrophic lateral sclerosis (ALS) is a multi-factorial and multi-systemic pathology associated with motor neu-
ron degeneration, muscle atrophy and paralysis1. Although several of the pathological mechanisms have been 
understood2, ALS remains an invariably fatal disease for which no effective therapy is known. A range of genetic 
and environmental conditions has been associated with ALS. Interestingly, notwithstanding the highly variable 
etiology of ALS, both sporadic and familial forms of this disease display a remarkable similarity in terms of disease 
progression and clinical manifestations. A crucial biological mechanism that is seriously affected in ALS is the loss 
of effective connections between muscle and nerve. Mounting evidence suggests that the earliest presymptomatic 
functional and pathological changes occur distally in axons and at the neuromuscular junctions (NMJ)3,4. These 
changes precede, and can be independent of, the loss of cell bodies or alterations in other cell types already linked 
to the ALS disease process4–7. In keeping with these findings, we observed that the AChRs in human ALS muscles 
are less sensitive to ACh than denervated non-ALS muscles8. It has also been reported that muscle specific expres-
sion of the mutant SOD1 gene, one of the genes associated with the familial form of ALS, induces muscle atrophy, 
a significant reduction in muscle strength, mitochondrial dysfunction, microgliosis5 and neuronal degeneration9, 
thus suggesting that retrograde signals from muscle to nerve may contribute to synapse and axon damage. This 
indicates that skeletal muscle could be an important target for therapeutic interventions7,10. Therefore, ensuring 
that the muscles remain strong and active might help to maintain muscle performance in the face of dwindling 
motor neuron input. The neuromuscular system may be artificially stimulated either by electrical stimulation (ES) 
or by time-varying electromagnetic fields. It has been demonstrated that transcutaneous ES enhances mass and 
muscle function in the elderly by inducing anabolic pathways and negatively modulating muscular catabolism11. 
Unfortunately, ES activates cutaneous nociceptors, including A-delta high-threshold mechanoreceptors, C-fiber 
polymodal nociceptors and A-delta myelinated heat nociceptors, which result in painful and unpleasant sensa-
tions. Furthermore, the activation of the nociceptive pathways might evoke exaggerated cutaneous withdrawal 
flexor reflexes, which cause discomfort and exacerbate a patient’s spasticity12.
Neuromuscular magnetic stimulation (NMMS) has been proposed as an alternative, non-invasive, stimula-
tion technique. NMMS is a painless and well-tolerated procedure that does not induce high-intensity cutaneous 
electric fields or activate skin nociceptors13. However, up to now, the effects of NMMS on muscle performance in 
patients with ALS have not been investigated.
In the current study, we tested the hypothesis that NMMS can improve muscle function and strength in 
spinal-onset ALS patients. Here we examined the effects of NMMS in patients with ALS, analyzing and com-
paring the morpho-functional properties and related molecular markers of both treated and untreated muscles. 
Data were compared with records obtained from sham NMMS. The primary outcome was the evaluation of the 
efficacy and safety of NMMS in improving the muscular strength of the patient affected by ALS. Secondary out-
comes included the effect of NMMS on the following parameters: i. the electrophysiological changes (study of 
CMAP) to define the physiological mechanisms of rNMMS; ii. the analysis of the nicotinic ACh-evoked currents 
in muscles of ALS patients; iii. the histomorphometric parameters of the same ALS muscles, analyzing muscle 
fiber type composition, muscle atrophy and wasting; iv. the changes in gene expression of a selected panel of 
genes involved in muscle growth and atrophy. Outcome measures were completed at baseline and at the end of 
treatment. Potential adverse events, experienced by the patients, were monitored during the period of treatment 
and after 3 months follow-up period.
We demonstrate that repetitive NMMS improves muscle strength and function and activates a molecular 
circuit that counteracts muscle atrophy and strengthens the muscle in spinal-onset ALS patients, with a good 
tolerability.
Results
Twenty-two patients were enrolled in this study (19 male, 3 female). The patients’ mean age at the time of the 
baseline visit was 61.27 ± 13.44 years (range 37 to 81 years), while their mean disease duration was 26.82 ± 15.43 
months.
We randomized 22 patients, who completed and well tolerated the clinical study. Out of those, only 15 
patients underwent the needle-biopsy as 7 patients finally refused the procedure because of poor compliance. 
Unfortunately, the amount of muscle obtained with the percutaneous needle-biopsy was not always sufficient 
to carry out all the proposed analyses. Thus, according to the amount of muscle available 15 patients provided 
muscle samples for the electrophysiological study of the nicotinic AChRs, among these only 7 patients provided 
also samples for the molecular and the histological analysis. Additionally, 4 patients of the latter were selected for 
histomorphometric analysis. This selection was based on the possibility to count at least 50 fibers on a muscle 
cross section observed under light microscopy. The rNMMS did not evoke any significant muscle twitch and was 
a well-tolerated and painless stimulation procedure. The study design is represented in Fig. 1 and a flow chart 
showing details of patients’ allocation is represented in Fig. 2.
NMMs improves muscle strength. To determine whether rNMMS improves muscle strength, we used 
the MRC Muscle Scale for the upper limbs and a performed a handgrip dynamometer bilateral assessment before 
rNMMS (T0), at the end of rNMMS (T2) and 30 days after rNMMS ended (T3) (Fig. 3).
No significant differences in the MRC Muscle Scale at the flexor carpi radialis muscle (rNMMS: 3.95 ± 0.57 
vs sNMMS: 3.63 ± 0.84, p = 0.31, Mann-Whitney U test) and dynamometer values (rNMMS: 22.0 ± 6.2 Kg vs 
sNMMS: 19.9 ± 5.8 Kg, p = 0.71, Mann-Whitney U test) were observed between treated and untreated groups at 
the baseline (T0).
The results of the RM ANOVA with a Greenhouse-Geisser correction (sphericity not assumed) (Fig. 3) 
showed that rNMMS induced a significant effect [F(1.697, 35.630) = 19.583, p < 0.01] on the muscle strength, as 
measured by the handgrip dynamometer; the within-subject analysis demonstrated a significant post-stimulation 
increase in muscle strength (measured by dynamometer) compared with the pre-stimulation (T0), both at T1 
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(p = 0.001), and T2 (p = 0.0001) and a significant decrease in T3 (p = 0.004). The between-subject analysis showed 
a significant interaction dynamometer*group of treatment at T2 (p = 0.004). The same RM ANOVA analysis, 
with assumption of sphericity, showed a significant effect [F(3, 63) = 5.907, p < 0.01] of rNMMS on MRC scale at 
the flexor carpi radialis muscle; the within-subject analysis demonstrated a significant post-stimulation increase 
in MRC scale, compared with the pre-stimulation strength (T0), both at T1 (p = 0.008), and T2 (p = 0.005); a 
significant decrease was not observed at T3 (p > 0.05). No interaction MRC*group of treatment was found at any 
time point.
By contrast, no significant improvement in muscle strength was observed in the other untreated muscles, 
tested with the dynamometer at T1 (p = 0.847) and T2 (p = 0.086); a significant reduction in the muscle strength 
was found at T3 (p = 0.006). In order to verify whether the improvement in muscle strength was related to a col-
lateral sprouting of motor neurons, we performed a nerve conduction study (NCS) of the median motor nerve 
bilaterally; CMAPs were obtained from the APB and flexor carpi radialis muscles. No significant difference in 
CMAP amplitudes was observed before and after rNMMS (Fig. 3c,d).
NMMS preserves fast muscle fibers. To verify whether the improvement in muscle strength induced by 
rNMMS parallels the changes in the degree of muscle atrophy and/or fiber type composition, we performed his-
tological analyses (n = 7 patients) and morphometric measurements (n = 4 patients) on needle biopsies obtained 
at the end of the NMMS sessions (T2; Fig. 1) from both the rNMMS and contralateral sNMMS muscles. At the 
histological examination, all the ALS muscles displayed, regardless of the type of stimulation, a marked variability 
in fiber size because of numerous atrophic angulated fibers and sporadic groups of hypertrophic fibers (range 
of cross sectional fiber diameter: 8–86 μm in sNMMS muscle; 8–108 in rNMMS muscle) (Fig. 4a,b). Atrophy 
involved both slow and fast fiber types and was associated with fiber type grouping, which is consistent with the 
occurrence of previous reinnervation phenomena (Fig. 4c).
The morphometric analysis performed on sections immunostained with antibodies for either slow or fast 
myosin revealed that rNMMS significantly counteracted muscle atrophy in fast twitch fibers when compared 
with sNMMS (p < 0.001, regression model t-test). This effect was not observed in slow fibers, whose diameters 
instead displayed a slight, though significant, reduction in size (p < 0.01, regression model t-test) (Fig. 4d). These 
features were paralleled by a higher mean percentage of fast twitch fibers in rNMMS than in sNMMS muscles 
(66.10 ± 29.6% vs 49.22 ± 20.10%, p < 0.005, paired t-test).
NMMs acts on the function of muscular nicotinic ACh receptors. We used the membrane micro-
transplantation technique applied to Xenopus oocytes14 to overcome the technical and ethical difficulties to 
perform cellular electrophysiological recordings in muscles from ALS patients. The small amount of tissue col-
lected from the muscle biopsy of 15 patients (about 10 mg of muscle tissue) proved to be sufficient to evoke ACh 
currents when membranes were transplanted in the oocytes (range: 1.6–67.4 nA; n = 283; 15 patients; unless 
stated otherwise, the ACh concentration was 500 μM and the holding potential −60 mV). We observed that the 
amplitude of the ACh-evoked currents (IACh) was significantly higher in oocytes microtransplanted with rNMMS 
tissues than in untreated tissues (rNMMS: 10.61 ± 1 nA; n = 139; 15 patients vs sNMMS: 7.14 ± 0.6 nA; p = 0.036, 
Mann-Whitney rank sum test; n = 144; 15 patients) (Fig. 5a).
Moreover, we studied the decay time (T0.5) of the IACh during ACh long application in both sNMMS and 
rNMMS tissues. Our experiments showed that T0.5 (i.e. the time required for the IACh to reach half of its peak 
amplitude during the decaying phase) is faster following rNMMS than in sNMMS (rNMMS: 5.3 ± 1 s; n = 18; 
sNMMS: 9.6 ± 2 s; n = 16; p = 0.034, Mann-Whitney rank sum test; 4 out of 15 patients) (Fig. 5b). Taken together, 
these results indicate that rNMMS improves ACh function by modifying the AChR response. When we assessed 
ACh affinity in this study, we observed that the ACh dose-response curve for the rNMMS samples shifted to 
the left if compared with the sNMMS samples (sNMMS: 51 ± 0.4 µM; n = 18; vs rNMMS: 33.2 ± 2.7 µM; n = 16; 
p = 0.028, Mann-Whitney rank sum test; 4 out of 15 patients) (Fig. 5c).
Figure 1. Study design. BV (baseline visit) represents the screening of ALS patients; T0 is the first recording 
of clinical strength and neurophysiological parameters before stimulation, T1 after one week, and T2 after two 
weeks of stimulation; T3 is thirty days after the end of stimulation.
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Molecular mechanisms activated in response to rNMMs treatment counteract muscle atro-
phy. To determine the adaptation changes in gene expression due to rNMMS, we performed a real time PCR 
(RT-PCR) analysis to quantify shifts in mRNA levels of a selected panel of genes involved in muscle growth 
and plasticity in both rNMMS and sNMMS samples of 7 patients. The keys factors involved in skeletal muscle 
adaptations and growth are insulin-like growth factor-1 (IGF-1)15,16 and myostatin17,18. IGF-1 and myostatin play 
opposing roles in regulating the size of skeletal muscle, with the former stimulating and the latter inhibiting 
muscle growth.
Figure 6 shows that rNMMS did not induce any significant difference in the expression levels of either IGF-1 
(Fig. 6A) or myostatin (Fig. 6B) (IGF-1 rNMMS: 0.96 ± 0.27; p = 0.38; myostatin rNMMS: 0.73 ± 0.15; p = 0.16, 
Wilcoxon matched-pairs rank test), thus suggesting that the trophic action of rNMMS acts on alternative 
pathways.
Transcriptional up- or down-regulation of atrophy-related genes is a characteristic feature of muscle atrophy19. 
The most critical players involved in muscle atrophy are MAFbx/atrogin-1 and MuRF-1, which are muscle-specific 
atrophy-related ubiquitin ligases responsible for increased protein degradation through the ubiquitin-proteasome 
system. We found a significant down-regulation of MuRF-1 and a reduced trend in atrogin-1 expression in the 
rNMMS samples post-treatment (Fig. 6C and D) (MuRF-1 rNMMS: 0.62 ± 0.05; p = 0.002; atrogin-1 rNMMS: 
1.03 ± 0.16; p = 0.94, Wilcoxon matched-pairs rank test), which suggests that rNMMS preserved muscle mass 
by modulating protein catabolism. The maintenance of muscle mass is the result of the delicate balance between 
Figure 2. Flowchart diagram of the study.
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anabolic and catabolic processes. We thus investigated the level of SREBP-1, a transcription factor whose accu-
mulation has been associated with a decrease in the protein synthesis rate and with the negative modulation of 
muscle protein content20. As shown in Fig. 6E, we observed a significant down-modulation in SREBP-1 in the 
treated muscle biopsies compared with untreated biopsies, (SREBP-1 rNMMS: 0.61 ± 0.08; p = 0.003; Wilcoxon 
matched-pairs rank test), thereby confirming that rNMMS counteracts muscle atrophy by down-modulating 
proteolysis and attenuating the expression of protein synthesis inhibitors.
To lend further support to this hypothesis, we evaluated other key players involved in the homeostatic main-
tenance of skeletal muscle, namely MiR-24 and MiR-1, which are strongly induced during myogenesis and are 
maintained at high levels in terminally differentiated muscle tissues21. Figure 6F and G show a statistically sig-
nificant accumulation of both MiRNAs in treated muscle compared with untreated muscle (MiR-24 rNMMS: 
1.91 ± 0.43; p = 0.019, MiR-1 rNMMS: 2.37 ± 0.50; p = 0.012, Wilcoxon matched-pairs rank test).
NMMs treatment attenuates muscle denervation in ALs patients. Samples obtained from biopsies 
of 7 ALS patients display signs of denervation and reinnervation of muscle fibers and the upregulation of the γ 
subunit of AChR in ALS muscles10. Here we show that rNMMS modulated the regulatory circuit of muscle-nerve 
interplay22, up-regulating MiR-206 (Fig. 7A) and down-regulating HDAC4 (Fig. 7B), myogenin (Fig. 7C) as well 
as the γ (Fig. 7D) and α (Fig. 7E) subunits of the AChR (MiR-206 rNMMS: 2.21 ± 0.47; p = 0.019, HDAC4 
rNMMS: 0.43 ± 0.08; p = 0.02; myogenin rNMMS: 0.61 ± 0.14; p = 0.047 AChR-γ rNMMS: 0.47 ± 0.10; p = 0.004 
Wilcoxon matched-pairs rank test; AChR- α rNMMS: 0.55 ± 0.17; p = 0.02 t-test).
Mef2c is reported to be up-regulated in ALS muscle23 and to be reduced by MiR-206 upregulation in type II 
reinnervated fibers24. To verify whether MiR-206 up-regulation correlates with the modulation of Mef2c and with 
maintenance of muscle fiber composition, we investigated the transcript level of Mef2c in rNMMS-treated ALS 
samples and in sNMMS samples. Figure 7F shows a significant down-modulation in Mef2c transcript levels in the 
rNMMS arm compared with the sNMMS arm (Mef2c rNMMS: 0.68 ± 0.13; p = 0.04 t-test).
Discussion
This study shows the efficacy of localized rNMMS treatment in improving muscle strength, while reducing mus-
cle atrophy and alteration in molecular markers of the functional interplay between muscle and nerve. A signifi-
cant improvement in muscle strength was observed in the treated arm as tested by the MRC Muscle Scale and by 
dynamometer. The increase in muscle strength measured by dynamometer was significantly higher in the treated 
compared to untreated muscle at T2. These results suggest that rNMMS induces a focal improvement in muscle 
strength. This effect progressively decreased after the end of rNMMS (T3) for the dynamometer and the MRC 
Muscle Scale, probably because of the natural progression of the disease. Interestingly, the CMAP amplitude 
remained the same before and after stimulation, thereby suggesting that the improvement was not related to 
Figure 3. Significant improvement in muscle strength of the flexor carpi radialis muscle. (a) Muscle strength 
was tested by means of the MRC Muscle Scale and (b) handgrip dynamometer after NMMS. No significant 
improvement in muscle strength was observed in the control group. (c) No significant difference in cMAP 
amplitudes was observed before and after NMMS in the APB and (d) flexor carpi radialis muscles after median 
motor nerve stimulation at the elbow (Data represent mean ± SEM).
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reinnervation phenomena25. Moreover, the increase in muscle strength was limited to the treated muscle, which 
indicates that the effect of rNMMS is localized, with no action being exerted on the distal muscles owing to the 
decay in the magnetic field.
Muscle atrophy and weakness are among the first signs of ALS disease, even before motor neuron degener-
ation is observed26. A modulation of muscle protein catabolism as down-modulating of MuRF-1 and atrogin-1 
expression, an attenuation of the expression of protein synthesis inhibitors as SREBP-1, and an increase of factors 
involved in the homeostatic maintenance of skeletal muscle, as MiRNAs were evidenced at the end of the NMMS 
treatment.
One important characteristic of skeletal muscles is their plasticity, which is needed to modulate their prop-
erties in response to a wide range of external factors, including physical and motor-neuron activity, changes in 
Figure 4. Morphologic and morphometric analysis of untreated and NMMS treated muscles. (a) Hematoxylin 
and eosin staining of muscle biopsies in sNMMS- and (b) rNMMS-treated muscles display grouped atrophy 
and scattered hypertrophic fibers (scale bar 50 µm). (c) Immunohistochemical staining for slow and fast myosin 
show that the majority of the fast fibers are atrophic in the representative sNMMS muscle (upper panel). The 
contralateral rNMMS-treated muscle (lower panel) is characterized by a prevalence of fast fibers. (d) Density 
estimation of the diameter for fast and slow twitch fibers across 4 patients, showing a significant shift in the 
peak fast fiber diameter towards higher values in rNMMS (red line) if compared with sNMMS (black line) 
(p < 0.001).
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Figure 5. Electrophysiological analysis of ACh responses in sNMMS- and rNMMS. (a) The bar graphs show 
the mean ACh current amplitude (mean ± SEM) in sNMMS vs rNMMS injected oocytes. (Inset) Representative 
current traces from sNMMS (left) and rNMMS (right) injected oocytes. [ACh] = 500 μM; 4 s applications. 
*p < 0.05. Note the increase in current amplitude after rNMMS. (b) The bar graphs show the mean ACh current 
decay time (mean ± SEM) in sNMMS vs rNMMS injected oocytes. (Inset) Representative current traces from 
sNMMS (upper) and rNMMS (lower) injected oocytes. [ACh] = 500 μM; 30 s applications. *p < 0.05. Note the 
faster current decay time induced by rNMMS. (c) Averaged EC50 values in oocytes injected with membranes 
from sNMMS and rNMMS patients, showing an increase in ACh affinity after rNMMS treatment.
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hormone levels and oxygen and nutrient supply. One of the pathological features of ALS is a change in the muscle 
fiber profile, with a selective loss of fast-twitch fibers27–29 that is likely to be due to the selective vulnerability of 
fast fatigable and fast fiber-innervating motor neurons30. The morphometric analysis evidenced a higher mean 
percentage of fast twitch fibers in treated than in untreated muscles, thereby suggesting that rNMMS preserves 
fast fibers and consequently attenuates muscle atrophy.
Previous studies demonstrated that the diaphragm pacing had a deleterious effect on ALS patients with res-
piratory failure, as measured by overall survival; a possible explanation of this effect is that pacing may cause 
excessive muscle fatigue or that asynchrony between pacing-induced diaphragmatic contraction and patient- 
and/or NIV-triggered breaths may represent an issue. On the other hand, in line with our results, diaphragm 
pacing may induce a shift from a predominance of efficient type I fibres to inefficient type IIb fibres31. In contrast 
to the electrical stimulation, no significant muscle twitch was observed during the rNMMS sessions; this data – 
altogether with the lack of changes observed in the CMAP amplitudes registered before and after the stimulation 
protocol – suggests that the effect of the magnetic field is not likely exerted on motor nerves, but directly on mus-
cle fibers or on nerve-muscle connection.
Tirasemtiv is a fast skeletal muscle troponin activator (FSTA), which increases the contractile sarcomeric 
response by selectively binding to the fast skeletal muscle troponin complex, thus slowing the rate of calcium ion 
release and sensitizing the sarcomere to calcium32. Despite Tirasemtiv improved physical function in SOD1 trans-
genic mouse models of ALS, in a phase IIb trial the primary endpoint showed no treatment effect. Nevertheless, 
the primary endpoint and most of the secondary endpoints concerned certain respiratory milestones of disease 
progression, instead of direct muscle function measures. It is important to underline that quantitative muscle 
strength declined significantly more slowly on Tirasemtiv group.
Since rNMMS counteracts morphological changes and reduces atrophy in ALS muscles, we wondered 
whether rNMMS also modifies the electrophysiological function of nicotinic AChRs, which play a key role in 
muscular contraction. Our results confirm that rNMMS promotes the maintenance of AChR, increasing ACh 
affinity and restoring nAChR function to levels resembling those observed in non-ALS denervated patients. 
Indeed, we observed an improvement in the efficacy of ACh, as shown by the increase in ACh current ampli-
tude after rNMMS treatment. In addition, faster current decay correlates with the change in ACh affinity, which 
Figure 6. NMMS treatment counteracts muscle atrophy and enhances robustness and resistance to fibrosis in 
ALS muscles. (A) Real-time PCR analysis of IGF-1EA, (B) myostatin, (C) MuRF-1, (D) atrogin-1, (E) SREBP-1, 
(F) MiR-24, (G) MiR-1 transcript in rNMMS- and sNMMS-treated samples (**p < 0.01, *p < 0.05. The number 
above the graph indicates the percentage decrease in transcript expression in treated vs control samples. Data 
are represented as mean ± SEM).
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suggests that AChRs may be more inducible at low neurotransmitter doses. The improved electrophysiological 
function of the AChR might be a result of the down-modulation of proteolysis and of fibrotic processes induced 
by rNMMS and might partially explain the beneficial effects exerted by rNMMS stimulation on the contractile 
capability of the diseased muscle. The maintenance of the functional connection between nerve and muscle was 
revealed by the modulation of γ subunit containing AChR (AChRγ) after rNMMS treatment. AChRγ is expressed 
at high levels in muscle during embryonic development and perinatally, whereas its expression is low or unde-
tectable in normal active or disused adult muscle. By contrast, AChRγ expression increases in denervated muscle 
or under conditions that alter NMJ functionality6,33. Our data demonstrate that rNMMS treatment stabilizes the 
neuromuscular end plate and muscle maintenance. The mini-regulatory circuit that controls the muscle-nerve 
interplay involves the class IIa histone deacetylase-4 (HDAC4) and myogenin, a bHLH transcription factor whose 
expression is down regulated in adult skeletal muscle and induced in response to denervation22,34,35, which in 
turn promotes the activation of MuRF-1 and atrogin-136. Upon reinnervation signals, myogenin activates a key 
regulator of the bidirectional signaling between motor neurons and skeletal muscle fibers, namely MiR-206. MiR-
206 is reported to be dramatically induced in the mouse model of ALS and in denervated muscle fibers, in which 
it establishes a negative feedback loop that promotes muscle reinnervation and repression of HDAC4 expres-
sion37. We demonstrated that rNMMS up-regulates MiR-206, which in turn modulates HDAC4, myogenin and 
AChRγ, all of which act as important regulators of the signaling that detects nerve activity within the muscle. 
Our data clearly indicate that rNMMS improves muscle function and mass by regulating key factors and the 
signaling involved in nerve-muscle connection. Overall, this study represents and provides a first evidence that 
local rNMMS treatment of ALS patients enhances muscle strength and may consequently improve the daily life 
of such patients.
Interestingly, the clinical benefits of rNMMS result in a better hand function of the stimulated arm even after 
stimulation ends. It is therefore conceivable that this technique may be further developed to improve fine motor 
skills activities by increasing both the duration and the modality of NMMS stimulation. The recovery of some 
Figure 7. NMMS treatment stabilizes the neuromuscular end plate and preserves muscle fiber composition 
during disease progression. (A) Real-time PCR analysis of MiR-206, (B) HDAC4, (C) Myogenin, (D) AChRγ, 
(E) AChRα, (F) Mef2c transcripts in rNMMS- and sNMMS-treated samples (*p < 0.05 **p < 0.01. Data 
represent mean ± SEM).
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activities of daily living, such as holding a pencil or a spoon, are also considered to be critical issues by ALS treated 
patients owing to the psychological consequences associated with the inability to perform such activities.
This is in keeping with the concept of health-related quality of life (HRQoL) proposed by Shumaker and 
Naughtonas: “people’s subjective evaluations of the influences of their current health status, health care, and 
health-promoting activities on their ability to achieve and maintain a level of overall functioning that allows them 
to pursue valued life goals, and that is reflected in their general well-being”38. Thus, any therapeutic approach 
aimed at preserving HRQoL by improving some aspect of independence may be considered to be “clinically 
meaningful”.
The clinical data were supported by physiological and molecular changes that demonstrated the activation of 
local circuits that attenuate muscle weakness. Our data further support the so-called “dying-back” phenomenon 
and highlight the potential of therapeutic interventions designed to attenuate muscle dysfunction, NMJ changes 
and possibly even disease progression in a sort of “saving-back” process.
Thus, our work is consistent with a model (Fig. 8) in which rNMMS treatment prevents muscle atrophy, pre-
serves fiber type composition and stabilizes the neuromuscular junction, thereby enhancing the robustness of the 
muscles in ALS patients.
Undoubtedly, our study has important limitations. The small number of bioptic samples did not allow some 
statistical analyses or stratification for all variables, and an excessive multiple statistical analyses were also used 
seen the several clinical, molecular and morphological patterns investigated. We have chosen the percutaneous 
needle biopsy technique to make the patient’s collection less unpleasant, but the material obtained was not suffi-
cient to carry out completely the histological, histomorphometric and RNA analysis studies. Moreover, in spite 
of these aspects, the results obtained with different experimental approaches all lead to the same conclusion 
about the objective support of clinical improvement of muscle strength, through counteracting muscle atrophy 
(increase of growth factors that support muscle trophism), down-modulating of proteolysis (reduction of factors 
that favor atrophy) and increasing the efficacy of nicotinic AChRs. These unidirectional results reassure us on the 
validity of the results obtained.
Although optimism about the use of rNMMS as a novel translational approach to the treatment of ALS, this 
work is a proof of concept study without an immediate clinical translation. Moreover, this intervention should 
be analyzed on more global ALS progression parameters (overall survival, ALSFRS-R score, pulmonary function 
tests). It is possible that the same technique might be difficult to adapt to different clinical forms of ALS, given 
the underlying heterogeneity of the disease (i.e. bulbar-onset patients, upper motor neuron predominant involve-
ment, fast progression of the disease). Further studies, on both ALS patients and animal models, are needed to 
shed light on how local muscle-NMJ treatment can activate survival pathways at the spinal and cortical levels.
Methods
This single-center randomized double blind controlled study was designed to evaluate the efficacy of NMMS in 
spinal-onset (ALS) patients. Participants were subsequently randomly assigned in 1:1 ratio. Clinical trial was 
registered with number: NCT03618966; date of registration: August 07, 2018.
patients. Subjects were recruited from the ALS Center of Policlinico Umberto I, Sapienza University of Rome 
from November 2014 to November 2017. Inclusion criteria were: (i) diagnosis of probable or definite spinal-onset 
ALS according to electrodiagnostic criteria39, (ii) moderate degree of muscle atrophy, and (iii) bilateral sym-
metric muscular deficit in flexor carpi radialis muscle or flexor digitorum profundus muscle, as defined by a 
MRC Muscle Scale score of 3-4/5. Exclusion criteria included history of epilepsy or severe headaches, pregnancy 
or breast-feeding, the presence of an implanted cardiac pacemaker, neurostimulators, surgical clips or medical 
pumps, or any other comorbid condition that might prevent the patient from completing the study. Moreover, 
the patients previously treated with Transcranial Magnetic Stimulation (TMS) or NMMS were also excluded. The 
patients’ clinical characteristics are summarized in Table 1. The study was approved in 2014 by the Institutional 
Review Board of Policlinico Umberto I (reference 3314/25.09.14; protocol no. 1186/14) and performed in accord-
ance with the Declaration of Helsinki. All the patients provided written informed consent prior to inclusion in 
the study.
Figure 8. Schematic representation of NMMS effect on ALS muscle decline.
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experimental design. The follow-up for each patient lasted for 4 weeks. At the baseline visit, patients were 
randomized in two groups on the basis of a sequential number from a computer-generated random list. One 
group received real stimulation (rNMMS) in the right arm and sham stimulation (sNMMS) in the left arm in the 
same daily session; the other group received rNMMS in the left arm and sNMMS in the right arm. All the patients 
underwent a medial nerve conduction study (NCS) at T0 and T2 and a clinical examination at time T0, T1, T2 
and T3 (T0 was the first recording of clinical strength and neurophysiological parameters before stimulation, T1 
after one week of stimulation, T2 after two weeks of stimulation, T3 after thirty days of stimulation) (Fig. 1). The 
clinical examination included i) a handgrip strength test to measure the maximal isometric strength of the hand 
and flexor forearm muscles, and ii) MRC Muscle Scale to manually test the upper limb muscles. A needle muscle 
biopsy was performed bilaterally, under a local anesthetic, to obtain a flexor carpi radialis muscle sample for the 
histological, physiological and molecular studies at T2. After three months from the end to the study, the patients 
underwent a new clinical visit to also evaluate potential side effects. Patients and physicians who performed all 
examinations were blinded to the allocation of real/sham intervention, except one physician (MI), who did the 
randomization process and performed the NMMS treatment supported by a neurophysiopathologist technician 
(GT). The subjects involved in the study, namely people who performed the clinical evaluation (CC, EO, MCG), 
the electrophysiological examinations (MC, VF), the histological and histomorphometric analysis (AP, BC, CG), 
the RNA preparation and real-time analysis (AM, GD, EL) and the electrophysiological recordings (GR, PC, EP, 
CR) were blinded to the subject’s treatment.
Motor NCS was performed using a Micromed Myoquick 1400 EMG machine (Micromed S.p.A., Treviso, 
Italy); Ag/AgCl surface electrodes were applied according to a conventional belly-to-tendon method. Filter set-
tings were 5 Hz–5 kHz, sweep duration was 30 ms and sensitivity was 1 mV/division. The median nerve was stim-
ulated at the elbow, bilaterally, and the maximal cMAP amplitude was recorded from the APB and flexor carpi 
radialis muscles. To ensure that the electrodes were positioned correctly at T0 and T2, a henna pinpoint tattoo 
was applied to mark the center of the muscle being studied. The MRC Muscle Scale grades the patient’s strength 
in 8 pairs of muscles for the upper limbs on a scale of 0–5. The handgrip strength test was performed by asking the 
patient to hold and then squeeze, with the arm at a right angle and the elbow by the side of the body, a dynamom-
eter with maximal effort for three seconds; the mean value from three trials was recorded in Kg for each side, with 
30-second recovery period after each trial.
No changes to methods after trial commencement were needed.
primary and secondary outcomes. The primary outcome was the evaluation of the efficacy and safety 
of NMMS in improving the muscle strength of patients affected by ALS according to MRC-score. Secondary out-
comes included the effect of rNMMS on: 1. the muscular strength measured with handgrip dynamometer; 2. the 
electrophysiological changes (CMAP) to define the physiological mechanisms of the rNMMS; 3. the analysis of 
ACh evoked currents from bioptic muscles; 4. the histomorphometric parameters of muscle of ALS patients, ana-
lyzing muscle fiber type composition, muscle atrophy and wasting; 5. the changes in gene expression of a selected 
panel of genes involved in muscle growth and plasticity through a real time PCR (RT-PCR) analysis. Outcome 
measures were completed at baseline and at the end of each treatment phase. Potential adverse events, experi-
enced by the patients, were monitored during the period of treatment and during the 3 months follow-up period.
MEAN SD
Age (years) 61.27 13.44
Disease duration (months) 26.82 15.43
ALSFRS-R (tot) 35.55 6.82
FVC (%) 80.14 16.91
MRC Muscle Scale (upper limbs)
stimulated 31.73 4.17
not stimulated 29.59 5.25
MRC flexor carpi radialis
stimulated 3.95 0.57
not stimulated 3.63 0.85
Dynamometer (Kg)
stimulated 22.0 6.2




  not stimulated 3.24 3.3
Flexor carpi radialis muscle
stimulated 11.48 5.17
not stimulated 9.59 5.81
Table 1. Clinical characteristic at T0 of the 22 patients included in the study (19 males. 3 females). Data are 
expressed as mean ± standard deviation (SD).
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NMMs. All the patients received daily real and sham repetitive NMMS sessions, for five days a week for two 
consecutive weeks. Real NMMS was delivered by means of a high-frequency magnetic stimulator (Magstim 
Rapid – The Magstim Company Ltd., Whitland, South West Wales, UK) connected to a conventional cooled 
coil (Magstim AFC Coil). The magnetic stimulator was placed over the flexor muscles of the forearm. rNMMS 
was delivered at a 5-Hz frequency at 100% of the maximum intensity in 140 trains of 50 stimuli; the inter-train 
interval was 15 seconds. Sham NMMS was performed using a sham coil inserted in the same magnetic stimulator 
(Magstim AFC Coil), inducing a very shallow magnetic field. This weak magnetic field replicates the sensation 
of rNMMS without deep activation and with the production of similar acoustic sensations and with mechanical 
skin perceptions as rNMMS40.
Bioptical procedure. A needle muscle biopsy (TSK Acecut Biopsy Needle 14Gx150 mm) under a local anes-
thetic was performed bilaterally from flexor carpi radialis muscle for histological, physiological and molecular 
studies in the treated and in the untreated arms at the end of the NMMS treatment.
The biopsy site was infiltrated with about 2 cc of lidocaine intradermally and subcutaneously with a 25 G nee-
dle to anesthetize the subcutaneous tissue and muscle fascia in order to avoid distorting the muscle sample to be 
biopsied. The needle was introduced perpendicularly into the muscle, and the inner cannula was open for about 
30–45 seconds, allowing the suction to draw in a muscle sample. The procedure was repeated 2–3 times until an 
adequate sample was obtained.
Histological analysis. Serial 5-micrometre (µm) cryostat sections from each biopsy were stained with 
hematoxylin and eosin (HE) for the morphological analysis and immunostained with antibodies again fast, slow 
and fetal myosin (Novocastra, MI, Italy) to evaluate the distribution of fiber types. A total of 14 samples were 
analyzed (rNMMS and sNMMS arms from 7 patients).
Histomorphometric analysis. To quantify the degree of muscle atrophy, a histomorphometric analysis was 
performed on 4 out of 7 selected patients and rNMMS and sNMMS muscles immunostained with fast or slow 
myosin. The muscle was selected only if afforded the possibility to count at least 50 fibers (up to 140) per muscle 
section. The frequency distribution of the slow- and fast-twitch fiber diameter was evaluated for each muscle 
biopsy. High-resolution images were acquired at 10 and 20X magnification using a digital camera (Olympus) and 
analyzed by means of a dedicated software (ImageJ 1.47 v, Wayne Rasband National Institutes of Health, USA). 
The effect of rNMMS treatment on the diameter size was evaluated for each fiber type by means of a regression 
model that accounted for patient heterogeneity.
RNA preparation and real-time analysis. Total RNA from human muscle biopsies of 7 patients was 
isolated by TRIzolTM reagent (Thermo Fisher Scientific); total RNA (1 μg) was reverse-transcribed using the 
QuantiTect Reverse Transcription Kit (Quiagen), while 10 ng of RNA were reverse-transcribed using the TaqMan 
micro RNA Reverse Transcription Kit (Thermo Fisher Scientific). Quantitative PCR was performed using the ABI 
PRISM 7500 SDS (Thermo Fisher Scientific), Taqman universal MMIX II (Thermo Fisher Scientific) and TaqMan 
probe (Thermo Fisher Scientific). The quantitative RT-PCR sample value was normalized for the expression of 
GAPDH and U6 snRNA for mRNA and microRNA, respectively. The relative expression was calculated using 
the 2−ΔΔCt method41 and reported as a fold change.
Membrane reparation, injection procedures, and electrophysiological recordings from 
oocytes. Human muscle samples (about 10 mg) of 15 patients were frozen in liquid nitrogen immediately 
after biopsy and stored at −80 °C. Membranes were prepared as previously detailed14. Membrane currents were 
recorded from voltage-clamped oocytes 24–48 h after injection using two microelectrodes filled with 3 M KCl. 
The oocytes were placed in a recording chamber (volume, 0.1 mL) and perfused continuously, 9–10 mL/min, with 
oocyte Ringer’s solution (OR) at room temperature (20–22 °C). Unless otherwise specified, the oocytes were volt-
age clamped at −60 mV and acetylcholine (ACh) was 500 μM, 4 s application. In a subset of experiments (4 out of 
15 patients, randomly selected) we applied ACh for 30 s to measure the ACh current desensitization defined as the 
time taken for the current to decay from its peak value to half-peak value (T0.5). Acetylcholine (ACh; Tocris) was 
dissolved in OR just before use. Data were analyzed using Sigma Plot 12 software and are given as means ± SEM; 
datasets were considered statistically different when p < 0.05. All the electrophysiological experiments were per-
formed in blind fashion.
statistical Methods
Based on a previous study on measurement of muscle strength in healthy seniors before and after electrical stim-
ulation training, also using the variation of muscle function after treatment with NMMS as a primary outcome, 
and assuming a pooled standard deviation of 4.9 units, the sample size was defined 11 patients per group to obtain 
a statistically significant result with 80% of power and a level of significance of 5% (two sided)11. Taking into 
account a 40% drop-out, it was decided to enroll at least 16 patients per group.
All details related to statistical tests, statistical parameters, including sample sizes and significance are reported 
in the results section. Graph values are reported as mean ± standard error of the mean (SEM). Statistical evalua-
tion for the study of muscular nicotinic AChRs was performed using Mann-Whitney U test; for morphometric 
analysis of 4 selected biopsies was performed using the regression model t-test; for mRNA levels of selected panel 
of genes was performed by Wilcoxon matched-pairs rank test; for the muscle strength was performed using a RM 
ANOVA with a Greenhouse-Geisser correction (sphericity not assumed). Data were considered statistically signif-
icant when p < 0.05. Statistical analysis was performed using either Sigmaplot 12 or GraphPad PRISM 6 software.
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Data Availability
All the data and protocol details are available from the corresponding authors upon request.
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